Mark McCabe

Mark McCabe is a seasoned Medical Science Liaison with expertise in inflammatory bowel disease for Takeda Pharmaceuticals in Sydney, Australia. He brings a wealth of experience from diverse scientific backgrounds.

Mark's previous roles encompass oncology, immuno-oncology, endocrinology, rare diseases, and neurology at prestigious institutions in Melbourne, Sydney, and London. His proficiency extends to communication, networking, and collaboration with key opinion leaders (KOLs), healthcare professionals (HCPs), industry representatives, and internal stakeholders.

He has played a pivotal role in various initiatives, including establishing the world's first clinically accredited whole genome sequencing biotechnology company, Genome.One. Mark is well-versed in medical review of promotional materials, moderation of webinars, and establishment of clinical trial projects and SOPs.

With a strong academic background, Mark holds a PhD in Applied Biology/Biotechnology focusing on Male Reproductive Endocrinology, along with a First Class Honours and Bachelor's Degree with Distinction from RMIT University.

Apart from his scientific endeavors, Mark has excelled in business management, overseeing a restaurant for 8.5 years. He is also a private pilot license holder and a sports enthusiast, particularly of cricket and AFL football, supporting the Collingwood team. Mark is a dual national of Australia and Britain.